AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 114 min read$PLUR

Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare

HAIFA, Israel, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Pluri Inc. ( "Pluri", the "Company", "we", "our" or "us" ) ( Nasdaq, TASE: PLUR ) , a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the ...

Original reporting
GlobeNewswire · Pluri Inc.
Published Nov 11, 2025, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 12, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$PLURBullishHigh
01

Why it matters

The partnership signifies a strategic move to expand product offerings and market reach, likely boosting investor confidence.

02

Market read

The news is highly relevant to biotech and cosmetic sectors, with potential to influence stock prices and investor sentiment.

03

What to watch

Possible delays in product development or regulatory hurdles could temper positive expectations.

Timing: immediate, as the news is recent and market reaction is ongoing.

Background

Pluri Inc. is a biotech company specializing in cell-based solutions, leveraging proprietary platforms for regenerative medicine.

Company-level read

Ticker impact

$PLURBullishHigh confidence
Context

Primary focus due to the company's announcement and market sentiment.

Expected impact

Moderate upward movement in the short to medium term, potentially 5-10% increase within 1-3 weeks.

Evidence & confidence

The partnership with a high-profile brand like Miss Universe Skincare enhances Pluri's market visibility and credibility in biotech and cosmetic sectors, supporting positive stock movement.

Market effects

Sector

Potential positive impact on biotech and cosmetic sectors, especially companies involved in exosome technologies.

Regional

Primarily affects Israeli biotech sector and global markets where Pluri operates.

Global

Moderate, as the partnership enhances Pluri's international profile and may influence global biotech and cosmetic markets.

Counterpoint

What could challenge this read

Market may have already priced in the news, leading to limited additional upside; potential overestimation of partnership impact.

Key entities

  • Company
    Pluri Inc.

    A leading Israeli biotechnology firm specializing in cell-based solutions.

  • Brand
    Miss Universe Skincare

    A global skincare brand partnering with Pluri to develop exosome-enhanced products.

Read at source← All news

Related articles

AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min
AUG 28
$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

yahoo.com3 min
AUG 28
$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

wisbusiness.com3 min
AUG 28
$EXCMed

Why Exelon's CFO is stepping into a new strategy role

Exelon's CFO Jeanne Jones transitions to a new role as EVP of finance and strategy on Oct. 5, focusing on long-term strategy and capital allocation. Robert Kleczynski will succeed Jones as CFO. Exelon reported Q2 revenue of $5.97 billion, up 10% YoY, beating estimates. The company is investing in infrastructure amid rising electricity demand and pressure to keep customer bills affordable.

fortune.com2 min